Salix Pharmaceuticals Newswire (Page 4)

Salix Pharmaceuticals Newswire (Page 4)

Comprehensive Real-Time News Feed for Salix Pharmaceuticals. (Page 4)

Results 61 - 80 of 278 in Salix Pharmaceuticals

  1. What You Need to Know About Arrivo BioVenturesRead the original story

    Jan 8, 2017 | BioSpace

    January 9, 2017 By Mark Terry , Breaking News Staff Arrivo BioVentures , based in Morrisville, N.C., is focused on accelerating biologics and small molecules through clinical development. Its expertise is in fast, efficient and high-quality drug development.


  2. Valeant Pharmaceuticals Intl. Inc.'s Biggest Catalysts in 2017Read the original story w/Photo

    Jan 3, 2017 | Fox News

    ... Papa has also suggested that he and his team are open to the idea of selling Valeant's core assets (Salix Pharmaceuticals and/or Bausch & Lomb) for the "right price." Now here's the dilemma Valeant faces: Its peers are fully aware of its struggles ...


  3. Synergy Pharmaceuticals: Prospects Are Better Than EverRead the original story w/Photo

    Dec 30, 2016 | Seeking Alpha

    ... but now it's being investigated to treat IBS-C. Take, for example, Xifaxan (Rifaximin), from Salix Pharmaceuticals, a branch of Valeant Pharmaceuticals (NYSE: VRX ). Though first discovered in Italy in 1987, it's still under marketing exclusivity ...


  4. Inflammatory bowel diseaseRead the original story w/Photo

    Dec 21, 2016 | Nature

    ... finds out (see ). We are also pleased to acknowledge the financial support of Salix Pharmaceuticals in producing this Outlook. As always, Nature has sole responsibility for all editorial content.


  5. The Valeant Pharmaceuticals Exodus Continues -- Only This Time It's InternalRead the original story w/Photo

    Dec 13, 2016 | Fox News

    ... thus don't want to pay a premium for its assets. On the flip side, if Valeant sells core assets like Salix Pharmaceuticals or Bausch & Lomb, which is something Papa hasn't ruled out for the right price, it could give up a big pathway to future ...


  6. 3 Toxic Value Stocks to Avoid in 2017Read the original story w/Photo

    Dec 7, 2016 | Fox News

    ... not making a big enough dent in its debt load. If it sells its core assets, such as Bausch & Lomb or Salix Pharmaceuticals, it'll knock out a good portion of its debt, but it'll also cripple its growth prospects moving forward. As icing on the cake, ...


  7. Surprise! The SEC Isn't Happy With Valeant Pharmaceuticals AgainRead the original story w/Photo

    Dec 5, 2016 | The Motley Fool

    ... point is what will Valeant divest -- its non-core assets or its core assets, such as Bausch & Lomb and Salix Pharmaceuticals? Neither pathway offers a particularly inviting outcome. If Valeant attempts to sell its non-core assets, which comprise ...


  8. 3 Prime Reasons Valeant Pharmaceuticals Intl. Inc. Shares Dove 11% in NovemberRead the original story w/Photo

    Dec 5, 2016 | The Motley Fool

    ... to make a dent in its debt load. However, if it winds up selling its juiciest core assets, like Salix Pharmaceuticals or Bausch & Lomb, then it will likely crush its future growth potential. Plus, no matter which path Valeant takes, its prospective ...


  9. 3 Reasons To Hold Valeant PharmaceuticalsRead the original story w/Photo

    Dec 4, 2016 | Seeking Alpha

    ... for funding their clinical studies. Markets reacted badly to Valeant's failure to solidify a sale of Salix Pharmaceuticals to Takeda, because the $30 billion will cost more to service in the years ahead. Valeant faces headwinds from high debt ...


  10. 3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017Read the original story w/Photo

    Dec 1, 2016 | Fox News

    ... be able to take a significant bite out of its debt by selling its core assets (i.e. Bausch & Lomb or Salix Pharmaceuticals), but it would also likely cripple its future growth prospects in the process. Even Valeant's flagship businesses are ...


  11. Valeant Pharmaceuticals Intl Inc (VRX) To Retain Salix...Read the original story w/Photo

    Dec 1, 2016 | Insider Monkey

    Buyout talks between Valeant Pharmaceuticals Intl Inc and Takeda Pharmaceutical Co Ltd that would have resulted in the sale of Salix Pharmaceuticals, Ltd. , which Valeant owns, have broken down. The negotiations could be revived, but Valeant doesn't seem keen on resuming talks to sell its Salix business as it has already begun talking about strengthening the business on its own.


  12. Valeant Said to Plan to Keep Salix After Takeda Deal Falls Apart an hour agoRead the original story

    Nov 30, 2016 | Bloomberg

    ... sold $40 million. Together, they made up about 13 percent of the company's third-quarter revenue. Salix Pharmaceuticals Inc. was acquired by Valeant in a March 2015 deal the companies said was worth $11.1 billion. Chief Executive Officer Joe Papa, ...


  13. WSJ: Valeant's Talks to Sell Salix Break Down; Shares DropRead the original story w/Photo

    Nov 30, 2016 | News Max

    Valeant Pharmaceuticals International Inc. fell as much as 10 percent Wednesday after The Wall Street Journal reported that the Canadian drugmaker had reached an impasse talks to sell its stomach-medicine business. The talks might be revived, but Valeant is now focused on building the business, Salix Pharmaceuticals, rather than selling it, according to unnamed sources cited by the newspaper .


  14. Valeant's talks have broken down on selling stomach-drug business...Read the original story w/Photo

    Nov 30, 2016 | Wall Street Journal

    ... the matter. Though the talks could still be revived, Valeant is now focused on building the business, Salix Pharmaceuticals, rather than selling it, the people said.


  15. Biotech Forum Daily Digest: A Shift In Sentiment? M&A Rumors Pick Up; Spotlight On InvitaeRead the original story w/Photo

    Nov 25, 2016 | Seeking Alpha

    ... up that Valeant Pharmaceuticals (NYSE: VRX ) will sell the GI assets acquired through its purchase of Salix Pharmaceuticals (NASDAQ: SLXP ) in 2015 in a deal for up to $10 billion to Takeda. A sale, if it happens, can only be good for Progenics ...


  16. Valeant: Change Is GoodRead the original story w/Photo

    Nov 24, 2016 | Seeking Alpha

    Fellow contributor Giovanni DiMauro published a bearish take on Valeant Pharmaceuticals with which I strongly disagree. I'll start by going over DiMauro's points where I hold a variant view and summarize my bullish take at the end.


  17. 3 Stocks That Have Been Complete Turkeys in 2016Read the original story w/Photo

    Nov 24, 2016 | Fox News

    ... non-core or core Valeant assets. Furthermore, if Valeant sells its core assets (Bausch & Lomb and/or Salix Pharmaceuticals), it could give up much of its future growth prospects. But that might be needed to get its debt reduced to a reasonable ...


  18. Faith, Feedback And Fear: Ready For The Valeant Test?Read the original story w/Photo

    Nov 22, 2016 | Seeking Alpha

    It is easier and more fun to write about your winners than your losers, but it is also far more important and valuable to revisit your losers, where the story has not played out the way you hoped it would. It is important because it is easy to lapse into denial and hold on to your losers too long, not only because you let hope override good sense, but also because the act of selling is the ultimate admission that you made a mistake.


  19. RedHill Biopharma Ltd. (RDHL) Downgraded to "Sell" at Zacks Investment ResearchRead the original story

    Nov 17, 2016 |

    ... gastroenteritis and IBS-D; RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA - an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal ...


  20. Finally Some Good News for Valeant Pharmaceuticals and Its ShareholdersRead the original story w/Photo

    Nov 17, 2016 | Fox News

    ... load, is its long-term growth prospects. CEO Joseph Papa has suggested that Valeant's core assets, Salix Pharmaceuticals and Bausch and Lomb, are possibly for sale if the company gets the right price in return. Selling these assets would more than ...